Literature DB >> 22304418

Protein G, protein A and protein A-derived peptides inhibit the agitation induced aggregation of IgG.

Jun Zhang1, Elizabeth M Topp.   

Abstract

Controlling and preventing aggregation is critical to the development of safe and effective antibody drug products. The studies presented here test the hypothesis that protein A and protein G inhibit the agitation-induced aggregation of IgG. The hypothesis is motivated by the enhanced conformational stability of proteins upon ligand binding and the specific binding affinity of protein A and protein G to the Fc region of IgG. The aggregation of mixed human IgG from pooled human plasma was induced by agitation alone or in the presence of (i) protein A, (ii) protein G or (iii) a library of 24 peptides derived from the IgG-binding domain of protein A. Aggregation was assessed by UV spectroscopy, SDS-PAGE, high performance size-exclusion chromatography (HP-SEC), dynamic light scattering (DLS) and fluorescence spectroscopy. Additional information on IgG-ligand interactions was obtained using differential scanning fluorimetry (DSF) and competitive binding studies. The results demonstrate that protein A provides near-complete inhibition of agitation-induced aggregation, while protein G and two peptides from the peptide library show partial inhibition. The findings indicate that the IgG protein A-binding site is involved in the agitation-induced aggregation of IgG, and suggest a dominant role of colloidal interactions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22304418      PMCID: PMC3295918          DOI: 10.1021/mp200548x

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  24 in total

1.  Convergent solutions to binding at a protein-protein interface.

Authors:  W L DeLano; M H Ultsch; A M de Vos; J A Wells
Journal:  Science       Date:  2000-02-18       Impact factor: 47.728

Review 2.  The state of antibody therapy.

Authors:  Ali Elbakri; Paul N Nelson; Raed O Abu Odeh
Journal:  Hum Immunol       Date:  2010-09-16       Impact factor: 2.850

Review 3.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

Review 4.  Protein stability, flexibility and function.

Authors:  Kaare Teilum; Johan G Olsen; Birthe B Kragelund
Journal:  Biochim Biophys Acta       Date:  2010-11-19

5.  Effect of sugar molecules on the viscosity of high concentration monoclonal antibody solutions.

Authors:  Feng He; Christopher E Woods; Jennifer R Litowski; Lauren A Roschen; Himanshu S Gadgil; Vladimir I Razinkov; Bruce A Kerwin
Journal:  Pharm Res       Date:  2011-05-15       Impact factor: 4.200

Review 6.  Recombinant immunotherapeutics: current state and perspectives regarding the feasibility and market.

Authors:  Chung-Jr Huang; Adam J Lowe; Carl A Batt
Journal:  Appl Microbiol Biotechnol       Date:  2010-04-27       Impact factor: 4.813

7.  Role of the dimethylbenzimidazole tail in the reaction catalyzed by coenzyme B12-dependent methylmalonyl-CoA mutase.

Authors:  S Chowdhury; R Banerjee
Journal:  Biochemistry       Date:  1999-11-16       Impact factor: 3.162

8.  Inhibition of agitation-induced aggregation of an IgG-antibody by hydroxypropyl-beta-cyclodextrin.

Authors:  Tim Serno; John F Carpenter; Theodore W Randolph; Gerhard Winter
Journal:  J Pharm Sci       Date:  2010-03       Impact factor: 3.534

9.  Thermolability of mutant MMACHC protein in the vitamin B12-responsive cblC disorder.

Authors:  D S Froese; S Healy; M McDonald; G Kochan; U Oppermann; F H Niesen; R A Gravel
Journal:  Mol Genet Metab       Date:  2010-02-15       Impact factor: 4.797

10.  Ligand-binding by catalytically inactive mutants of the cblB complementation group defective in human ATP:cob(I)alamin adenosyltransferase.

Authors:  Jun Zhang; Xuchu Wu; Dominique Padovani; Heidi L Schubert; Roy A Gravel
Journal:  Mol Genet Metab       Date:  2009-06-27       Impact factor: 4.797

View more
  3 in total

1.  Physical Characterization and Innate Immunogenicity of Aggregated Intravenous Immunoglobulin (IGIV) in an In Vitro Cell-Based Model.

Authors:  E M Moussa; J Kotarek; J S Blum; E Marszal; E M Topp
Journal:  Pharm Res       Date:  2016-04-01       Impact factor: 4.200

2.  Structure based descriptors for the estimation of colloidal interactions and protein aggregation propensities.

Authors:  Michael Brunsteiner; Michaela Flock; Bernd Nidetzky
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

Review 3.  Structure and Aggregation Mechanisms in Amyloids.

Authors:  Zaida L Almeida; Rui M M Brito
Journal:  Molecules       Date:  2020-03-06       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.